Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Large Drop in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 44,811 shares, a decrease of 72.4% from the May 14th total of 162,618 shares. Based on an average trading volume of 99,259 shares, the short-interest ratio is presently 0.5 days. Currently, 3.9% of the shares of the company are short sold.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is owned by institutional investors.

Ernexa Therapeutics Trading Down 6.1%

Ernexa Therapeutics stock traded down $0.40 during trading hours on Friday, reaching $6.15. 27,962 shares of the stock were exchanged, compared to its average volume of 137,248. The company has a market cap of $7.20 million, a P/E ratio of -0.23 and a beta of 2.49. Ernexa Therapeutics has a twelve month low of $3.18 and a twelve month high of $71.50. The stock has a 50 day moving average of $7.48 and a two-hundred day moving average of $16.24.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). On average, analysts expect that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ERNA shares. Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target on the stock. Wall Street Zen downgraded shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.